Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Weekly Rifapentine and Isoniazid in Pregnant Women with Latent TB
NCT02651259Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of rifapentine in Tuberculosis (TB) (2 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Clearance Relative to Bioavailability for Rifapentine at 12 weeks, Clearance Relative to Bioavailability for Desacetyl Rifapentine at 12 weeks and 3 more. Started Mar 2017; status: completed.
02
Drugs
rifapentine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02651259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02651259.